GE HealthCare Technologies Inc. logo
GEHCGE HealthCare Technologies Inc.

Is the EPS diluted high or low?

The EPS diluted of 4.55 is in line with its 5-year average of 4.24, near the high end of its 5-year range (3.02–4.90).

2.36% above its 12-month average of 4.45.

EPS Diluted

GEHC EPS Diluted

0.85

Reported quarterly diluted EPS; no daily interpolation.

-33.49% 5Y
GEHC EPS Diluted

GEHC Average EPS Diluted Chart

GEHC EPS Diluted

GEHC Current vs Average EPS Diluted Chart

GEHC EPS Diluted Metrics

EPS DILUTED

4.55

EPS DILUTED AVG TTM

4.45

EPS DILUTED AVG 3Y

4.03

EPS DILUTED AVG 5Y

4.24

EPS DILUTED AVG 10Y

N/A

EPS DILUTED AVG 15Y

N/A

EPS DILUTED AVG 20Y

N/A

CURRENT VS TTM AVG

+2.36%

CURRENT VS 3Y AVG

+12.83%

CURRENT VS 5Y AVG

+7.31%

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

EPS Diluted Formula & Definition

EPS Diluted includes the effect of convertible securities, options, and other potential shares. Compare it with basic EPS to see the impact of potential dilution.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EPS Diluted FAQ

What is the EPS diluted for GE HealthCare Technologies Inc. (GEHC)?
The EPS diluted for GEHC stock is 4.55.
Is GE HealthCare Technologies Inc.'s EPS diluted high or low?
The EPS diluted of 4.55 is in line with its 5-year average of 4.24, near the high end of its 5-year range (3.02–4.90).
What is the TTM average EPS diluted for GE HealthCare Technologies Inc. (GEHC)?
The TTM average EPS diluted for GEHC stock is 4.45.
What is the 3Y average EPS diluted for GE HealthCare Technologies Inc. (GEHC)?
The 3Y average EPS diluted for GEHC stock is 4.03.
What is the 5Y average EPS diluted for GE HealthCare Technologies Inc. (GEHC)?
The 5Y average EPS diluted for GEHC stock is 4.24.

GEHC EPS Diluted History

DATEEPS DILUTED
2025-12-314.55
2024-12-314.34
2023-12-313.02
2022-12-314.22
2021-12-314.90
2020-12-314.41
2019-12-313.35

About GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

Chicago, IL
53,000 employees
Healthcare / Medical - Healthcare Information Services
Sector
Healthcare
Industry
Medical - Healthcare Information Services
CEO
Peter J. Arduini